In short
A new clinical trial is exploring the potential of combining IPH5201 with durvalumab and standard chemotherapy in treating early-stage non-small cell lung cancer (NSCLC). This study aims to assess the safety and effectiveness of this combination therapy as a neoadjuvant (before surgery) and adjuvant (after surgery) treatment for patients with resectable NSCLC at stages II to IIIA. The trial, known as MATISSE, offers hope for improving outcomes in early-stage lung cancer patients.
At a glance
- Study Type
- Phase II, multicenter, open-label, non-randomized
- Participants
- Patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (NSCLC)
- Treatment
- Neoadjuvant: IPH5201 + durvalumab + standard chemotherapy; Adjuvant: IPH5201 + durvalumab
- Primary Outcomes
- Pathological Complete Response (pCR), Adverse events (AEs) and serious adverse events (SAEs)
- Secondary Outcomes
- Event-Free Survival (EFS), Disease Free Survival (DFS), Surgical resection, Major Pathological Response (mPR), Objective Response Rate (ORR), Overall Survival (OS)
- Follow-up Duration
- Up to approximately 2 years
What is IPH5201?
IPH5201 is a new drug being studied for the treatment of non-small cell lung cancer (NSCLC). It is being tested in combination with another drug called durvalumab (also known as MEDI4736 or IMFINZI) and standard chemotherapy. This combination therapy is being investigated as a potential new treatment option for patients with early-stage NSCLC.
Target Condition: Non-Small Cell Lung Cancer
The clinical trial is focusing on patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer. NSCLC is a type of lung cancer that accounts for about 80-85% of all lung cancers. "Resectable" means that the cancer can be surgically removed, which is typically the case for early-stage lung cancers.
Treatment Approach
The treatment approach in this study involves two main phases:
- Neoadjuvant therapy: This is treatment given before surgery. Patients will receive IPH5201, durvalumab, and standard chemotherapy. The chemotherapy may include combinations like carboplatin/paclitaxel, pemetrexed/cisplatin, or pemetrexed/carboplatin.
- Adjuvant therapy: This is treatment given after surgery. Patients will receive IPH5201 and durvalumab.
This approach aims to shrink the tumor before surgery (neoadjuvant phase) and then prevent cancer recurrence after surgery (adjuvant phase).
Clinical Trial Details
The clinical trial, named MATISSE, is a Phase II study. It is described as an open-label, single-arm, multicenter study. Here's what these terms mean:
- Open-label: Both the researchers and patients know which treatment is being given.
- Single-arm: All participants receive the same treatment; there is no control group.
- Multicenter: The study is conducted at multiple hospitals or research centers.
Expected Outcomes
The researchers will be looking at several outcomes to determine if the treatment is effective and safe. These include:
- Pathological Complete Response (pCR): This means there are no cancer cells found in the removed tumor tissue after surgery.
- Major Pathological Response (mPR): This indicates a significant reduction in cancer cells in the removed tumor tissue.
- Event-Free Survival (EFS) and Disease-Free Survival (DFS): These measure how long patients live without their cancer progressing or returning.
- Overall Survival (OS): This measures how long patients live after starting the treatment.
Safety Monitoring
Patient safety is a crucial aspect of this clinical trial. The researchers will be closely monitoring for any side effects or complications. They will track:
- Adverse events (AEs): Any unfavorable medical occurrences during the study.
- Serious adverse events (SAEs): Any severe or life-threatening events.
Additionally, the researchers will be studying how the drugs interact in the body (pharmacokinetics or PK) and whether patients develop antibodies against the study drugs (anti-drug antibodies or ADA).